ArticleEuropean journal of medical research2025
Exploring the role of mitochondrial dysfunction-related genes in osteoporosis using weighted gene co-expression network analysis and machine learning.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence for Osteoporosis Diagnosis, Risk Prediction and Therapy: Current Advances, Clinical Challenges, and Future Perspectives.Clinical interventions in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoporosis (OP) is a prevalent age-related disease characterized by bone loss and increased fracture risk. Mitochondrial dysfunction is tightly associated with OP pathogenesis. This study aimed to explore the role of mitochondrial dysfunction-related genes (MDRGs) in OP.
methodsDifferentially expressed genes (DEGs) were identified from OP transcriptomic data sets, and weighted gene co-expression network analysis was performed to determine OP-associated modules. Machine learning algorithms (Random Forest, Support Vector Machine, and Lasso) were applied to identify hub MDRGs. Gene set enrichment analysis (GSEA) and regulatory network analysis were performed to elucidate their functions and regulatory interactions. Hub gene's expression was validated in tissues using immunofluorescence, and osteogenic induction assays were conducted to validate the biological role and mechanism of the key gene VPS35 in osteoblast differentiation.
resultsALAS1, HSPB1, and VPS35 were identified as hub MDRGs, with VPS35 showing good diagnostic performance. GSEA highlighted potential molecular pathways associated with hub genes in OP, such as TNF-NFκB, RAS-ERK, and RAS-PI3K signaling pathways. In addition, a regulatory network involving hub genes, miRNAs, and lncRNAs was preliminarily constructed, providing insights into possible regulatory mechanisms underlying OP. Experimental validation demonstrated that VPS35 overexpression inhibited osteoblast differentiation by suppressing the ERK/PI3K/AKT signaling pathways, and this progression was regulated by miR-142-5p.
conclusionsThis study reveals the potential roles of MDRGs in OP pathogenesis. VPS35 acts as a negative regulator of osteogenic differentiation by inhibiting ERK and PI3K/AKT signaling, providing preliminary insights into mitochondrial regulation of bone metabolism and potential therapeutic targets for OP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.